Signs of a turnaround for the exchange’s problem child – Business Week

Signs of a turnaround for the exchange's problem child – Business Week

One of the exchange’s big problem child may be facing a turnaround. The analysts will find plenty of good signs for the share.

ROBOTS TAKE OVER
Now, the robots take over financial jobs

THE WEEK buying and selling tips
“Two newcomers – one you should take out and one that is too expensive”
“Buy shares that have already risen 60 percent”

“NEW CHANCE TO GET HOME SAFE MONEY”
After Lifco successful introduction has now VA’s analysts from Börspodden once again found an opportunity to bring home safe money ” .

MANY SIGNS OF REVERSAL OF COURSE loser
After an unexpectedly weak half-year report from Elekta again lowered forecasts, analysts Corps came to different conclusions. Not infrequently seen, however, positive comments and to radiation therapy company can actually be facing a turnaround.

According to the analysis Direkt noted the following Thursday’s report.

* Swedbank Markets raises its recommendation to buy. The Bank believes that Elekta will be able to turn the ship and points out that the second quarter probably represented the bottom. A gradual recovery ahead to the abandoned forecast of 7-9 percent sales growth offers a great upside.

* Morgan Stanley raises its recommendation to overweight. The last year has been tough for radiation therapy company but the analysts believe that the company faces a turnaround. Certainly, some investors have lost confidence in Elekta but with the significantly lowered the forecast, there may be reason to look at the company with new eyes according to Morgan Stanley

* Jefferies goes the other way and lowers its recommendation to underperform.

* Societe Generale maintained its buy recommendation but lowers its price target by a fifth to 110 crowns. The bank also think here on a fundamental turnaround but points out that it requires patience.

* Pareto Securities reiterates its sell recommendation and price target of 65 crowns. Analysis Hall points out that medical technology company must do a really good second half to meet its expectations. Someone who Pareto do not really believe in.

* Danske Markets reiterates its buy recommendation but lowered the price target to 90 crowns. Bank complain, however, that there is light at the end of radiation therapy tunnel. Improved cash flow, positive comments about the Versa HD and gamma knife Gamma and the continued recovery of software sales in the US are posted on the plus side.

* ABG Sundal Collier reiterates its retention recommendation but lowers its price target by 5 crowns to 73 crowns. Bank notes a number of plus factors such as gross margin and cash flow. Although the bank likes the long sighting opportunities, warned that results disappointments. The valuation itself is not appealing enough to recommend the purchase, according to the ABG.

* DNB Markets reiterates its buy recommendation but lowers its price target to 85 from SEK 100. There is good potential in the longer term there are risks shorter-term notes bank which justifies the price target cut but longer-term prospects gives köpbränsle.

* SEB Equities reiterates its retention recommendation, which was sunk earlier in the week from purchase. The focus is now directed to the company’s growth opportunities in terms of sales and profit after previously focused on cash flow and accounting principles. Target price is lowered slightly to 82 crowns.

* Carnegie reiterates its buy recommendation with a price target lowered to 95 crowns. The share is also added to Carnegie’s so-called Mover list. The valuation of the Elekta has fallen and is now slightly below the main rival Varian’s valuation. The bank also says that the company faces a turnaround and sales and profits will improve significantly in the coming quarters. In addition, there are signs that it lacerated cash flow is about to recover.

At 11:50 o’clock on Friday was listed medical technology shares up around 7 percent to 76 crowns. On Thursday, however, fell nearly 4 percent share in the wake of the disappointing report, however, after substantial price fluctuations. So far this year Elekta shares dropped 23 percent.